Literature DB >> 18972726

[Effects of substance-partitioned moxibustion on plasma beta-EP content in the patient with primary dysmenorrhea of cold-damp stagnation type in the menstrual period].

Yan-Fen She1, Li-Hong Sun, Ji-Jun Yang, Jian-Jun Ge, Xin-Hua Li, Yong-Jian Lu.   

Abstract

OBJECTIVE: To probe into the mechanism of substance-partitioned moxibustion in treatment of primary dysmenorrhea (PD) of cold-damp stagnation type.
METHODS: The treatment group (105 cases of PD) were treated with substance-partitioned moxibustion and the control group (104 cases) were treated with Chinese drug Yueyue-shu. Their therapeutic effects were observed. Plasma beta-endorphin contents in menstrual period were determined before and after treatment in 40 patients of each group.
RESULTS: The total effective rate of 95.2% in the substance partitioned moxibustion group was better than 85.6% in the control group (P < 0.05); after treatment, plasma beta-endorphin content significantly increased in the substance-partitioned moxibustion group (P < 0.01).
CONCLUSION: Substance-partitioned moxibustion has obvious therapeutic effect on primary dysmenorrhea of cold-damp stagnation type, which is carried out possibly through regulating the plasma beta-endorphin content as one of the mechanisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972726

Source DB:  PubMed          Journal:  Zhongguo Zhen Jiu        ISSN: 0255-2930


  2 in total

Review 1.  Acupuncture for dysmenorrhoea.

Authors:  Caroline A Smith; Mike Armour; Xiaoshu Zhu; Xun Li; Zhi Yong Lu; Jing Song
Journal:  Cochrane Database Syst Rev       Date:  2016-04-18

2.  Moxibustion for primary dysmenorrhea: A resting-state functional magnetic resonance imaging study exploring the alteration of functional connectivity strength and functional connectivity.

Authors:  Han Yang; Xiang Li; Xiao-Li Guo; Jun Zhou; Zhi-Fu Shen; Li-Ying Liu; Wei Wei; Lu Yang; Zheng Yu; Jiao Chen; Fan-Rong Liang; Si-Yi Yu; Jie Yang
Journal:  Front Neurosci       Date:  2022-08-30       Impact factor: 5.152

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.